

Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis

Nandinee Patel, MD,^a Kok Wee Chong, MD,^b Alexander Y. G. Yip, BSc,^c Despo Ierodiakonou, MD, PhD,^d Joan Bartra, MD, PhD,^e Robert J. Boyle, MD, PhD,^a and Paul J. Turner, FRCPCH, PhD^a *London, United Kingdom; Singapore; Nicosia, Cyprus; and Barcelona, Spain*

Background: Regulatory bodies recommend that all patients at risk of anaphylaxis be prescribed 2 epinephrine autoinjectors, which they should carry at all times. This is in contrast to some guidelines. The proportion of anaphylaxis reactions that are treated with multiple doses of epinephrine has not been systematically evaluated.

Objective: Our aim was to undertake a systematic review and meta-analysis of published studies reporting epinephrine treatment for anaphylaxis in which data relating to the number of doses administered were available.

Methods: We searched the Medline, Embase, and Cochrane databases for relevant studies reporting at least 10 anaphylaxis events (due to food or venom) from 1946 until January 2020. Data were extracted in duplicate for the meta-analysis, and the risk of bias was assessed. The study was registered under the PROSPERO identifier CRD42017069109.

Results: A total of 86 studies (36,557 anaphylaxis events) met the inclusion criteria (20 of the studies [23%] were prospective studies; 64 [74%] reported reactions in the community, and 22 [26%] included food challenge data). Risk

of bias was assessed as low in 50 studies. Overall, 7.7% of anaphylaxis events from any cause (95% CI = 6.4-9.1) were treated with multiple doses of epinephrine. When only epinephrine-treated reactions for which subsequent doses were administered by a health care professional were considered, 11.1% of food-induced reactions (95% CI = 9.4-13.2) and 17.1% of venom-induced reactions (95% CI = 11.3-25.0) were treated with at least 1 epinephrine dose.

Heterogeneity was moderate to high in the meta-analyses, but at sensitivity analysis it was not affected by study design or anaphylaxis definition.

Conclusion: Around 1 in 10 anaphylaxis reactions are treated with at least 1 dose of epinephrine. (J Allergy Clin Immunol 2021;■■■:■■■-■■■.)

Key words: Epinephrine, allergic reaction, anaphylaxis, autoinjector device, refractory anaphylaxis

Epinephrine is established as the first-line treatment for anaphylaxis.¹ The majority of allergic reactions occur in the community.² Delayed administration of epinephrine has been associated with poor outcomes in anaphylaxis.^{3,4} To mitigate against this, patients at risk of anaphylaxis to food and insect stings are often prescribed epinephrine autoinjectors (EAI) for self-administration.

National and international regulatory agencies, including the US Food and Drug Administration, the Medicines and Healthcare Products Regulatory Agency in the United Kingdom, and the European Medicines Agency recommend that individuals at risk of anaphylaxis carry at least 2 EAI at all times.⁵ This is in contrast to guidelines from some specialist societies, which make this recommendation for only selected “at-risk” patients.⁶⁻⁹ This divergence in advice is potentially problematic for clinicians, who might be faced with medicolegal consequences if they go against official recommendations from regulatory authorities and prescribe only a single EAI device.

A number of observational studies have assessed the frequency of anaphylaxis reactions that fail to adequately respond to a single dose of epinephrine.^{2,6,10-15} However, the data are limited by the studies’ small sample sizes and differences in local practice in defining and treating anaphylaxis and heterogeneity in study design. As a result, estimates for the rate of allergic reactions treated with more than a single dose of epinephrine vary widely, ranging from 0%¹⁶ to 32%.⁶ We therefore undertook a systematic review and meta-analysis to assess the proportion of anaphylaxis reactions reported in the literature that were treated with at least 2 doses of epinephrine.

From ^athe National Heart and Lung Institute, Imperial College London; ^bthe Allergy Service, Department of Paediatric Medicine, KK Women’s and Children’s Hospital, Singapore; ^cthe School of Medicine, Imperial College London; ^dthe Department of Primary Care and Population Health, University of Nicosia Medical School; and ^ethe Hospital Clínic de Barcelona.

This research was funded by a UK Medical Research Council Clinician Scientist award to P.J.T. (reference MR/K010468/1). N.P., R.J.B., and P.J.T. are supported through the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare National Health Service (NHS) Trust and Imperial College London. The views expressed in this article are those of the author(s) and do not necessarily reflect those of the NHS, NIHR, or the Department of Health.

Disclosure of potential conflict of interest: P. J. Turner reports grants from the UK Food Standards Agency, JM Charitable Foundation, NIHR/Imperial Biomedical Research Centre and End Allergies Together, outside the submitted work; reports personal fees from the UK Food Standards Agency, DBV Technologies, Aimmune Therapeutics, Allergenis, and ILSI Europe outside the submitted work. R. J. Boyle reports grants from the UK Food Standards Agency, personal fees from Protia Therapeutics, DBV Technologies, the Cochrane Collaboration, and John Wiley & Sons on behalf of Clinical and Experimental Allergy, as well as personal fees from giving expert testimony outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication January 27, 2021; revised February 25, 2021; accepted for publication March 24, 2021.

Corresponding author: Paul J. Turner, FRCPCH, PhD, National Heart & Lung Institute, Imperial College London, Norfolk Place, London, W2 1PG. E-mail: p.turner@imperial.ac.uk.

0091-6749

© 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<https://doi.org/10.1016/j.jaci.2021.03.042>

Abbreviations used

EAI: Epinephrine autoinjector
 FAAN: Food Allergy and Anaphylaxis Network
 IPD: Individual patient data
 NIAID: National Institute of Allergy and Infectious Diseases

METHODS

This systematic review was registered at inception with PROSPERO (identifier CRD42017069109). The study is reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement 2009 and Meta-analysis of Observational Studies in Epidemiology recommendations.^{17,18}

Search strategy and eligibility/inclusion criteria

We searched Medline, Embase, and the Cochrane Register of Controlled Trials, including all primary records from 1946 to July 2019 that referred to anaphylaxis in response to food or venom triggers, which included data with respect to the use of epinephrine (for search strategies and terms, see [Tables E1-E3](#) in this article's Online Repository at www.jacionline.org). The search was updated in January 2021 by using the same methodology to include relevant studies published between July 2019 and December 2020. Eligible studies included those reporting more than 10 cases of anaphylaxis (by any definition) in individuals of all ages and in any country; the requirement for at least 10 cases was to minimize selection bias. We included both prospective and retrospective data, including data from food challenges conducted under medical supervision and patient surveys in which the categorization of anaphylaxis was evaluated by a health care professional (for further details, see the [Methods](#) section of the Online Repository at www.jacionline.org). No language restrictions were made, and we planned to include non-English articles if they met our inclusion criteria. We excluded data relating to adverse events following immunotherapy, as well as data sets that reported fatal anaphylaxis exclusively. Abstracts were independently screened by 2 researchers, and disagreements were resolved by discussion with a third team member. We also reviewed reference lists of included studies and review articles to identify other relevant studies. In cases in which potentially eligible studies did not report the number of epinephrine doses given, those studies' authors were contacted to determine whether these additional data could be provided.

Data extraction and additional data

Data were extracted in duplicate (by J.B., K.W.C., N.P., and A.Y.), and any discrepancies identified were resolved by discussion and consensus with a third reviewer (P.J.T.). When needed, authors were contacted for clarifications. The screening process was undertaken using Endnote X8. For all studies, we extracted data relating to the proportion of study-defined anaphylaxis treated with more than a single dose of epinephrine, and we noted whether the definition used was that published by the National Institutes of Allergy and Infectious Diseases (NIAID)/Food Allergy and Anaphylaxis Network (FAAN).¹⁹ Authors were asked to provide further data to determine the proportion of reactions that involved objective cardiovascular and/or lower respiratory signs (which we termed *cardiorespiratory anaphylaxis*). We also extracted data with respect to the number of epinephrine-treated reactions as the denominator, given that anaphylaxis is frequently not treated with epinephrine and conversely, some nonanaphylaxis reactions are treated with epinephrine.⁶ We also noted whether epinephrine doses were administered by a health care professional to facilitate sensitivity analyses. Risk of bias was assessed in duplicate (by N.P. and K.W.C.) using the approach of Hoy et al.²⁰

Data analysis and statistical methods

Meta-analysis of proportions (Meta Package, R project, version 4.0.3) was undertaken by using an inverse variance method for summary estimates of logit-transformed data in a random effects model, with a continuity correction of 0.5 for studies with zero events (Clopper-Pearson for CIs and restricted maximum likelihood estimator for heterogeneity estimates). In cases in which substantial heterogeneity existed, meta-regression of categorical and continuous variables was performed to assess for potential moderators (eg, publication year). For meta-analyses of at least 10 studies, tests for small-study effects were performed by using funnel plots to assess asymmetry and Egger tests (with use of weighted linear regression of the outcome on its SE).

We undertook the following prespecified subgroup analyses: by trigger (community reactions to food, supervised food challenge, and venom); patient age (adult, child younger than 18 years, or both). Sensitivity analyses were undertaken to assess how estimates varied according to the following: use of different definitions of anaphylaxis (study-defined anaphylaxis, reactions with cardiorespiratory signs, or reactions with any use of injected epinephrine); inclusion of only studies at low risk of bias, full-text publications only, and publication after 2006 (when the NIAID/FAAN clinical criteria for anaphylaxis were published)¹⁹; and studies in which subsequent epinephrine doses were given by a health care professional (presumably on the basis of a suboptimal response to the initial epinephrine dose).

RESULTS**Included studies and study/reaction characteristics**

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram for this systematic review is shown in [Fig 1](#). A total of 86 studies were eligible for inclusion (76 from the original search and a further 10 from when the search was updated in 2021),^{2,3,10-16,21-97} representing 88 data sets (2 studies reported both retrospective and prospective data sets in the same publication)^{14,16} and a total of 36,557 anaphylaxis events (see [Tables E13](#) and [E14](#)). A total of 35 studies reported food-induced reactions only, whereas 1 study reported venom-induced reactions only (see [Tables E4](#) and [E5](#)). Of the remaining 50 studies, trigger-specific data were available for 23. Risk of bias and individual study characteristics are reported in [Tables E6](#) and [E15](#), respectively (available in the Online Repository at www.jacionline.org) and summarized in [Table I](#). Of the 86 studies, 47 (55%) used the NIAID/FAAN criteria for anaphylaxis. Overall, epinephrine was administered in 50.4% of reactions (range 11.1%-100% across studies).

Rate of anaphylaxis reactions treated with more than 1 dose of epinephrine

Overall, at meta-analysis, 7.7% (95% CI = 6.4-9.1) of anaphylaxis reactions (all triggers) were treated with more than a single dose of epinephrine ([Fig 2](#)). We undertook sensitivity analyses to further refine this pooled estimate by limiting the definition of anaphylaxis to those reactions with objective cardiovascular or lower respiratory symptoms only (cardiorespiratory anaphylaxis) and those reactions for which epinephrine was administered. These estimates are reported in [Table II](#) (the corresponding forest plots are shown in [Figs 2](#) and [3](#), and see also [Figs E1-E18](#) [in the Online Repository at www.jacionline.org]). A slightly higher proportion of reactions (9.8% [95% CI = 7.8-12.2]) were treated with more than 1 dose of epinephrine when only cardiorespiratory anaphylaxis was considered. We also




FIG 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.


TABLE I. Summary of the included studies

Indicator	Any trigger	Food only	Venom only
Data sets available for meta-analysis (no.)			
Studies included	86	58	20
Available data sets	88	60	20
Data reports accidental reactions in the community	66	38	20
Study design (no.)			
Prospective	20/88	18/60	6/20
Retrospective	66/88	42/60	14/20
Both	2/88	0/60	0/20
Continent of study (no.)			
Europe	27	21	8
United States/Canada	38	24	8
Australia	12	8	3
Asia	11	7	1
Patient characteristics (no.)			
Children aged <18 years only	51	37	6
Adults only	3	2	0
Includes children and adults	34	21	14
Risk of bias (no.)			
Low	50	31	13
Moderate	36	27	7
High	2	2	0


performed a separate analysis limiting the numerator to include only those reactions for which any subsequent doses were given by a health care professional (on the basis that such doses would be given only if there was a suboptimal response to the first dose of epinephrine). In this analysis, the pooled estimates of anaphylaxis reactions treated with further doses of epinephrine by a health care professional were 7.0% (95% CI = 5.5%-8.9%) for food-induced reactions and 10.0% (95% CI = 5.1%-18.8%) for venom-induced reactions. For food reactions, the rate of subsequent administration of epinephrine was higher in cases of reactions resulting from allergen exposure in the community than in cases of anaphylaxis occurring at food challenge performed under medical supervision, but this difference was not statistically significant.

We also undertook sensitivity analyses assessing the impact of study design, risk of bias, publication after 2006, or full-text publications only (see Tables E9-E12 in the Online Repository). The only significant difference ($P < .001$) identified was for the comparison of prospective versus retrospective studies when subsequent doses were administered by a health care professional: in the prospective studies, an estimated 5.1% of anaphylaxis reactions (95% CI = 2.9-8.9%) were treated with more than 1 dose of epinephrine administered by a health care professional, whereas in the retrospective studies, the corresponding rate was 7.9% (95% CI = 6.5-9.7%) (see Table E9).

A Anaphylaxis reactions, all triggers



B Food-induced anaphylaxis



C Venom-induced anaphylaxis




FIG 2. Forest plots for the use of 2 (or more) doses of epinephrine to treat allergic reactions. A, All triggers. B, Food-induced reactions. C, Venom-induced reactions.

TABLE II. Summary of pooled estimates for all meta-analyses undertaken, by definition of anaphylaxis used

Indicator	Trigger, % of reactions treated with >1 dose of epinephrine					
	All		Food			Venom
	Any setting (n = 36,557)	Community (n = 34,121)	Any setting (n = 12,615)	Community (n = 10,179)	Food challenge (n = 2,436)	Any setting (n = 3,194)
Study-defined anaphylaxis	7.7% (6.4%-9.1%)	7.9% (6.5%-9.7%)	7.3% (5.8%-9.1%)	7.7% (6.5%-10.0%)	6.5% (4.2%-9.8%)	10.5% (6.2%-17.1%)
Cardiorespiratory anaphylaxis	9.8% (7.8%-12.2%)	9.6% (7.6%-12.1%)	9.7% (7.0%-13.4%)	9.1% (6.2%-13.1%)	10.8% (6.0%-18.8%)	11.1% (4.3%-26.0%)
Reaction treated with ≥1 dose of epinephrine	12.9% (11.2%-14.9%)	13.5% (11.5%-15.9%)	11.7% (9.9%-13.9%)	12.3% (9.9%-15.2%)	10.6% (7.9%-14.1%)	17.9% (13.2%-24.0%)
Reaction for which further epinephrine was administered by a health care professional	7.1% (5.8%-8.7%)	7.2% (5.7%-9.0%)	7.0% (5.5%-8.9%)	7.1% (5.3%-9.5%)	6.8% (4.4%-10.4%)	10.0% (5.1%-18.8%)
Epinephrine-treated reaction for which further epinephrine was administered by a health care professional	12.2% (10.4%-14.3%)	12.8% (10.6%-15.4%)	11.1% (9.4%-13.2%)	11.4% (9.1%-14.0%)	10.8% (8.0%-14.4%)	17.1% (11.3%-25.0%)

Further subgrouping of meta-analyses by reaction trigger (any trigger, food, or venom) and setting (community reactions, food challenges under medical supervision, or any setting) are listed. Data are presented as percentages (pooled estimates [95% CI]).

Heterogeneity and moderator assessment

Heterogeneity (as represented by I^2) was moderate to high for all meta-analyses (range 51.7%-99.5%). Assessment of the contribution of potential moderators to the overall heterogeneity for the all-trigger and food trigger data sets was undertaken by using prespecified variables, including age group, study design (prospective vs retrospective), and publication year. No evidence of a moderator effect was noted. We also explored the impact of study size on the pooled estimates. Funnel plots for all meta-analyses are provided in Fig E19 (in the Online Repository at www.jacionline.org). Mild asymmetry was noted for smaller studies, with a relative absence of small studies demonstrating higher proportions of multiple epinephrine use. Egger tests were performed for all of the meta-analyses (see Table E8 in the Online Repository at www.jacionline.org); we did not identify any statistical evidence of small-study effects in the various meta-analyses undertaken, with the exception of venom- and food-induced reactions irrespective of who administered the second epinephrine dose (when limited to second doses given by a health care professional, the small-study effect was not apparent). The risk of bias was low in 56%, 52%, and 65% of studies contributing to all-trigger, food-trigger, and venom-trigger meta-analyses, respectively.

Administration of 3 or more doses of epinephrine

A total of 11 studies reported the precise number of epinephrine doses administered. Overall, at least 3 doses were administered in 2.2% of anaphylaxis reactions (95% CI = 1.1%-4.1%) or in 3.4% of reactions treated with epinephrine (Table III^{10,13,14,21,22,40,48,72,76,84,87}).

DISCUSSION

This is the first systematic review in the literature in which meta-analysis was used to evaluate the rate of anaphylaxis

reactions treated with more than 1 dose of epinephrine. We found that approximately 1 in 10 reactions are treated with at least 1 additional epinephrine dose. This estimate did not change significantly in the sensitivity analyses, including when the data were limited to those reactions for which subsequent doses were administered by a health care professional (which arguably might reflect a higher degree of confidence in the persistence of anaphylaxis symptoms despite initial treatment with epinephrine). This estimate was robust despite a high degree of heterogeneity between the included data sets, reflecting differences in cohort characteristics, study design and setting, and anaphylaxis definition used. The majority of the data sets assessed anaphylaxis occurring in the community; it is therefore likely that these data are representative of the broader population of individuals with allergy.

One potential limitation is that we were unable to distinguish between the administration route or dose of epinephrine given, as these data were not available for most data sets. However, the majority of data included was related to initial doses given in the community via use of EAI. Excluding data sets published before 2006 (when the Joint Task Force on Practice Parameters published its recommendation that epinephrine be administered by the intramuscular route⁹⁸) did not demonstrate any significant impact on the pooled estimates. Furthermore, we did not find that year of publication was a significant moderator in heterogeneity across studies. Several data sets reported biphasic reactions; unfortunately, we were unable to clarify with study authors whether the data provided with respect to epinephrine administration was for the first or delayed phase of these reactions. Thus, we were unable to assess the need for more than 1 dose of epinephrine to treat late-phase reactions.

A strength of this meta-analysis is the high response rate from authors who were contacted to provide further clarification. Many authors shared anonymized raw data, which facilitated the analyses. However, the meta-analyses were undertaken by using





A Study-defined food-anaphylaxis**B** Food-anaphylaxis, treated with adrenaline**C** Study-defined food-anaphylaxis, 2nd dose given by HCP**D** Food-anaphylaxis, treated with adrenaline, 2nd dose by HCP

FIG 3. Forest plots for the use of 2 (or more) doses of epinephrine to treat food-related anaphylaxis occurring in the community as a result of accidental exposure. Study-defined anaphylaxis (**A**) and epinephrine-treated reactions only (**B**), irrespective of who administered the second (and subsequent) dose of epinephrine. Study-defined anaphylaxis (**C**), and only those epinephrine-treated reactions in which a subsequent dose of epinephrine was administered by a health care professional (HCP) (**D**).

aggregate data from individual studies rather than individual patient data (IPD). Although this allowed for inclusion of a greater number of studies, we were unable to further assess potential risk factors for the use of multiple epinephrine doses, which would have been possible with an IPD meta-analysis.

Given the inconsistencies in reported risk factors for multiple epinephrine use,^{10,11,13-15,21-23} an IPD meta-analysis would help address this evidence gap.

Recommendations vary with respect to the number of EAI that patients at risk of anaphylaxis should be prescribed—both

TABLE III. Total number of epinephrine doses given to individual patients receiving multiple doses of epinephrine

Study	% with food trigger	Proportion of anaphylaxis reactions treated with epinephrine				Proportion of epinephrine-treated reactions treated with multiple doses of epinephrine		
		1 Dose (%)	2 Doses (%)	3 Doses (%)	≥4 Doses (%)	2 Doses (%)	3 Doses (%)	≥4 Doses (%)
Järvinen et al, 2008 ⁴⁹	100%	77/95 (81%)	12/95 (13%)	6/95 (6.3%)	0/95 (0%)	12/95 (13%)	6/95 (6.3%)	0/95 (0%)
Manivannan et al, 2009 ¹⁰	33%	77/208 (37%)	25/208 (12%)	2/208 (1.0%)	0/208 (0%)	25/104 (24%)	2/104 (1.9%)	0/104 (0%)
Noimark et al, 2012 ⁷⁶	91%	28/245 (11%)	12/245 (4.9%)	1/245 (0.4%)	0/245 (0%)	12/41 (29%)	1/41 (2.4%)	0/41 (0%)
Brown et al, 2013 ⁴⁰	36%	130/315 (54%)	59/315 (19%)	39/315 (12%)	17/315 (5.4%)	59/245 (24%)	39/245 (16%)	17/245 (6.9%)
Campbell et al, 2015 ¹³	36%	281/582 (48%)	36/582 (6.2%)	6/582 (1.0%)	3/582 (0.5%)	36/326 (11%)	6/326 (1.8%)	3/326 (0.9%)
Nogic et al, 2016 ⁷²	75%	38/52 (73%)	10/52 (19%)	1/52 (1.9%)	0/52 (0%)	10/49 (20%)	1/49 (2.0%)	0/49 (0%)
Yanagida et al, 2017 ²²	100%	70/190 (37%)	18/190 (9.5%)	2/190 (1.1%)	0/190 (0%)	18/90 (20%)	2/90 (2.2%)	0/90 (0%)
Tsuang et al, 2018 ¹⁴	100%	197/221 (89%)	19/221 (8.6%)	4/221 (1.8%)	1/221 (0.5%)	19/221 (8.6%)	4/221 (1.8%)	1/221 (0.5%)
Anvari et al, 2019 ²¹	48%	218/275 (79%)	20/275 (7.3%)	5/275* (1.8%)	—	20/243 (8.2%)	5/243* (2.1%)	—
Gabrielli et al, 2019 ⁸⁷	79%	2276/3498 (65%)	234/3498 (6.7%)	36/3498 (1.0%)	12/3498 (0.3%)	234/2558 (9.1%)	36/2558 (1.4%)	12/2558 (0.5%)
Liu et al, 2019 ⁸⁴	38%	255/430 (59%)	34/430 (7.9%)	16/430* (3.7%)	—	34/305 (11%)	16/305* (5.2%)	—
Pooled estimate at meta-analysis (95% CI)		57% (41%-72%)	9.2% (7.2%-12%)	2.2% (1.1%-4.1%)		14% (11%-19%)	3.4% (1.9%-5.9%)	
				1.9% (1.0%-3.5%)	0.3% (0.1%-1.3%)		2.9% (1.7%-5.0%)	0.5% (0.1%-1.9%)

These data were available in 11 studies. The pooled estimate for each dosing bracket is provided as a percentage of either the total number of study-defined anaphylaxis reactions or epinephrine-treated reactions (95% CI).

*Data available only for 3 or more doses.

between countries and within a single country in which guidelines from specialist societies may contradict official government advice.⁵⁻⁹ Many anaphylaxis reactions resolve spontaneously without treatment,^{2,76} and in this analysis, we found that only 50.4% of anaphylaxis reactions were treated with *any* epinephrine, a rate that is consistent with the literature. It is clearly inappropriate to *not* treat anaphylaxis with epinephrine, which is rightly the universal recommendation in all international guidelines. A single dose of epinephrine may be insufficient to terminate a reaction for multiple reasons, including the following: reaction progression; underdosing (international guidelines recommend that teenagers and adults receive 0.5 mg of epinephrine, but for most EAI devices, the highest dose available is 0.3 mg of epinephrine); incorrect administration; subcutaneous administration, which is associated with a prolonged onset of action; delayed administration; and biphasic course of reaction. Our analysis, which is based on more than 25,000 anaphylaxis events, provides an important estimate of the frequency of multiple epinephrine doses given to treat anaphylaxis. Whether patients could be risk-stratified to assess the need for repeat doses of epinephrine requires further analysis, as is discussed in a recent publication by Shaker et al.⁹⁹

Conclusions

Around 10% of patients receiving epinephrine for anaphylaxis have a suboptimal response to a single dose of epinephrine, as assessed by a health care professional. These data are important in

informing guidance on the provision of EAI for patients at risk of anaphylaxis in the community.

We are grateful to our colleagues who authored the studies included for analysis and provided clarification when requested. In particular, we thank the following individuals, who kindly provided additional data for further analysis: Elissa Abrams, Waleed Alquarashi, Moshe Ben Shoshan, Helen Brough, Tin-Shan Chung, Neta Cohen, Anne Ellis, Sihui Goh, Linus Grabenhenrich, Toshiko Itazawa, Sarita Patil, Greg Shand, Jonathan Spengel, Britta Sundquist, Miguel Tejedor-Alonso, and Margitta Worm. We also thank Dianne Campbell (University of Sydney) for her early review of the protocol for this work.

Clinical implications: Around 10% of anaphylaxis reactions are treated with more than 1 dose of epinephrine, including when the decision to administer a further dose was made by a health care professional.

REFERENCES

- Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World Allergy Organization anaphylaxis guidance 2020. *World Allergy Organ J* 2020;13:100472.
- Grabenhenrich LB, Dölle S, Ruëff F, Renaudin JM, Scherer K, Pföhler C, et al. Epinephrine in severe allergic reactions: the European Anaphylaxis Register. *J Allergy Clin Immunol Pract* 2018;6:1898-906.e1.
- Lee S, Peterson A, Lohse CM, Hess EP, Campbell RL. Further evaluation of factors that may predict biphasic reactions in emergency department anaphylaxis patients. *J Allergy Clin Immunol Pract* 2017;5:1295-301.
- Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. *Clin Exp Allergy* 2000;30:1144-50.

5. European Medicines Agency: Epinephrine auto-injectors; better training tools recommended to support patients using epinephrine auto-injectors. Available at: https://www.ema.europa.eu/en/documents/referral/epinephrine-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients_en.pdf. Accessed December 28, 2020.
6. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al; EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. *Allergy* 2014; 69:1026-45.
7. Ewan P, Brathwaite N, Leech S, Luyt D, Powell R, Till S, et al. BSACI guideline: prescribing an epinephrine auto-injector. *Clin Exp Allergy* 2016;46:1258-80.
8. Australasian Society of Clinical Immunology and Allergy (ASCI) guideline for the acute management of anaphylaxis 2020. Available at: <https://www.allergy.org.au/hp/papers/acute-management-of-anaphylaxis-guidelines>. Accessed December 28, 2020.
9. Campbell RL, Li JT, Nicklas RA, Sadosty AT. Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. *Ann Allergy Asthma Immunol* 2014;113: 599-608.
10. Manivannan V, Campbell RL, Belloio MF, Stead LG, Li JT, Decker WW. Factors associated with repeated use of epinephrine for the treatment of anaphylaxis. *Ann Allergy Asthma Immunol* 2009;103:395-400.
11. Oren E, Banerji A, Clark S, Camargo CA Jr. Food-induced anaphylaxis and repeated epinephrine treatments. *Ann Allergy Asthma Immunol* 2007;99:429-32.
12. Banerji SA, Corel B, Garth AM, Clark S, Camargo C. Repeat epinephrine treatments for food-related allergic reactions that present to the emergency department. *Allergy Asthma Proc* 2010;31:308-16.
13. Campbell RL, Bashore CJ, Lee S, Bellamkonda VR, Li JT, Hagan JB, et al. Predictors of repeat epinephrine administration for emergency department patients with anaphylaxis. *J Allergy Clin Immunol Pract* 2015;3:576-84.
14. Tsuang A, Menon NR, Bahri N, Geyman LS, Nowak-Węgrzyn A. Risk factors for multiple epinephrine doses in food-triggered anaphylaxis in children. *Ann Allergy Asthma Immunol* 2018;121:469-73.
15. Inoue N, Yamamoto A. Clinical evaluation of pediatric anaphylaxis and the necessity for multiple doses of epinephrine. *Asia Pac Allergy* 2013;3:106-14.
16. Clark AT, Ewan PW. Good prognosis, clinical features, and circumstances of peanut and tree nut reactions in children treated by a specialist allergy center. *J Allergy Clin Immunol* 2008;122:286-9.
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; 283:2008-12.
18. Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Available at: <http://www.prisma-statement.org/>. Accessed December 28, 2020.
19. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second Symposium on the Definition and Management of Anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol* 2006;117:391-7.
20. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol* 2012;65:934-9.
21. Anvari S, Blackman AC, Anagnostou A. Insights from 275 cases of childhood anaphylaxis in the United States. *J Allergy Clin Immunol Pract* 2019;7:1696-9.e2.
22. Yanagida N, Sato S, Asaumi T, Ogura K, Ebisawa M. Risk Factors for severe reactions during double-blind placebo-controlled food challenges. *Int Arch Allergy Immunol* 2017;172:173-82.
23. Rudders SA, Geyer BC, Banerji A, Phipatanakul W, Clark S, Camargo CA Jr. Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis. *J Allergy Clin Immunol* 2012;130:1216-8.
24. Dogru M, Bostanci I, Ozmen S, Giniş T, Şenol HD. The features of anaphylaxis cases followed in the pediatric allergy clinic. *Güncel Pediatri* 2016;15:12-8.
25. van der Valk JP, Gerth van Wijk R, Dubois AE, de Groot H, Reitsma M, Vlieg-Boerstra B, et al. Multicentre double-blind placebo-controlled food challenge study in children sensitised to cashew nut. *PLoS One* 2016;11:e0151055.
26. Maris IH, O'Sullivan R, Daly D. Prospective study of the incidence of anaphylaxis in Irish children. *Allergy* 2015;70(suppl 101):296.
27. Topal E, Bakirtas A, Yılmaz O, Ertoý Karagöl IH, Arga M, Demirsoy MS, et al. Severe anaphylaxis in children: a single-center experience. *Pediatr Neonatol* 2014;55:320-2.
28. Chung T, Gaudet L, Vandenbergh C, Couperthwaite S, Sookram S, Liss K, et al. Pre-hospital management of anaphylaxis in one Canadian Urban Centre. *Resuscitation* 2014;85:1077-82.
29. Mulligan KD, Campbell T, Campbell D, Mehr S. Open food challenges in the office: are they safe? *Internal Med J* 2014;44(suppl 4):19.
30. Hsiao KCT, Robinson M, Simmons J, Smart J. Safety of paediatric oral food challenges in a tertiary private hospital. *Internal Med J* 2014;44(suppl 4):11.
31. Alqurashi W, Stiell I, Chan K, Neto G, Alsadoon A, Wells G. Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis. *Ann Allergy Asthma Immunol* 2015;115:217-23.e2.
32. Farias Aquino EG, Tejedor Alonso MA, Mugica Garica MV, Moro Moro M, Vila Albeld C, Rosado Ingelmo A, et al. Factors for the use of one or more doses of epinephrine in anaphylaxis episodes attended in a general hospital. *Allergy* 2013;68(suppl 97):449.
33. Abrams EM, Becker AB. Oral food challenge outcomes in a pediatric tertiary care center. *Allergy Asthma Clin Immunol* 2017;13:43.
34. Villafana-Soto KM, Joshi P, Wong M, Kakakios A, Campbell D. Safety of food challenges in a tertiary referral children's hospital. *Internal Med J* 2011; 41(suppl 4):5.
35. Arana NG, Bilbao A, Maruri M, Suinaga M, Escobal M. Anaphylaxis: a review of a series. *Allergy* 2009;64(suppl 90):493.
36. Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. *Ann Allergy Asthma Immunol* 2007;98:64-9.
37. White MV, Hogue SL, Bennett ME, Goss D, Millar K, Hollis K, et al. EpiPen4-Schools pilot survey: occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting. *Allergy Asthma Proc* 2015;36:306-12.
38. Manivannan V, Hyde RJ, Hankins DG, Belloio MF, Fedko MG, Decker WW, et al. Epinephrine use and outcomes in anaphylaxis patients transported by emergency medical services. *Am J Emerg Med* 2014;32:1097-102.
39. Johnson J, Malinowski A, Alving K, Lidholm J, Borres MP, Nordvall L. Ten-year review reveals changing trends and severity of allergic reactions to nuts and other foods. *Acta Paediatr* 2014;103:862-7.
40. Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, et al. Anaphylaxis: clinical patterns, mediator release, and severity. *J Allergy Clin Immunol* 2013;132:1141-9.e5.
41. Ben-Shoshan M, La Vieille S, Eisman H, Alizadehfard R, Mill C, Perkins E, et al. Anaphylaxis treated in a Canadian pediatric hospital: incidence, clinical characteristics, triggers, and management. *J Allergy Clin Immunol* 2013;132: 739-41.e3.
42. Turner PJ, Mehr S, Joshi P, Tan J, Wong M, Kakakios A, Campbell DE. Safety of food challenges to extensively heated egg in egg-allergic children: a prospective cohort study. *Pediatr Allergy Immunol* 2013;24:450-5.
43. Lee J, Garrett JP, Brown-Whitehorn T, Spergel JM. Biphasic reactions in children undergoing oral food challenges. *Allergy Asthma Proc* 2013;34:220-6.
44. Huang F, Chawla K, Järvinen KM, Nowak-Węgrzyn A. Anaphylaxis in a New York City pediatric emergency department: triggers, treatments, and outcomes. *J Allergy Clin Immunol* 2012;129:162-8.e83.
45. Rudders SA, Banerji A, Katzman DP, Clark S, Camargo CA Jr. Multiple epinephrine doses for stinging insect hypersensitivity reactions treated in the emergency department. *Ann Allergy Asthma Immunol* 2010;105:85-93.
46. Järvinen KM, Amalanayagam S, Shreffler WG, Noone S, Sicherer SH, Sampson HA, et al. Epinephrine treatment is infrequent and biphasic reactions are rare in food-induced reactions during oral food challenges in children. *J Allergy Clin Immunol* 2009;124:1267-72.
47. Arkwright PD. Automatic epinephrine device use in children with food allergies. *J Allergy Clin Immunol* 2009;123:267-8.
48. Järvinen KM, Sicherer SH, Sampson HA, Nowak-Węgrzyn A. Use of multiple doses of epinephrine in food-induced anaphylaxis in children. *J Allergy Clin Immunol* 2008;122:133-8.
49. De Swert LF, Bullens D, Raes M, Dermaux AM. Anaphylaxis in referred pediatric patients: demographic and clinical features, triggers, and therapeutic approach. *Eur J Pediatr* 2008;167:1251-61.
50. Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. *Ann Allergy Asthma Immunol* 2006;97:39-43.
51. Uguz A, Lack G, Pumphrey R, Ewan P, Warner J, Dick J, et al. Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaign. *Clin Exp Allergy* 2005;35:746-50.
52. Rueter K, Ta B, Bear N, Lucas M, Borland ML, Prescott SL. Increased use of epinephrine in the management of childhood anaphylaxis over the last decade. *J Allergy Clin Immunol Pract* 2018;6:1545-52.
53. Kondo A, Ishikawa K, Nagasawa H, Takeuchi I, Jitsuiki K, Ohsaka H, et al. An analysis of patients with anaphylaxis treated by a physician-staffed helicopter. *Air Med J* 2018;37:259-63.
54. Goh SH, Soh JY, Loh W, Lee KP, Tan SC, Heng WJK, et al. Cause and clinical presentation of anaphylaxis in Singapore: from infancy to old age. *Int Arch Allergy Immunol* 2018;175:91-8.

55. Tyquin BF, Hollinshead K, Mulligan K, Treloar M, Campbell D. Review of the use of epinephrine autoinjectors (EAI) in NSW Department of Education schools in terms 1 and 2 2017. *Internal Med J* 2017;47(suppl 5):20.
56. Noone S, Ross J, Sampson HA, Wang J. Epinephrine use in positive oral food challenges performed as a screening test for food allergy therapy trials. *J Allergy Clin Immunol Pract* 2015;3:424-8.
57. Capps JA, Sharma V, Arkwright PD. Prevalence, outcome and pre-hospital management of anaphylaxis by first aiders and paramedical ambulance staff in Manchester, UK. *Resuscitation* 2010;81:653-7.
58. Tiyyagura GK, Arnold L, Cone DC, Langhan M. Pediatric anaphylaxis management in the prehospital setting. *Prehosp Emerg Care* 2014;18:46-51.
59. Vijaykumar AL, Brathwaite N. Audit of anaphylaxis during food challenges at a paediatric day unit. *Clin Exp Allergy* 2017;47:1711.
60. Kim MY, Park CS, Jeong JW. Management and educational status of adult anaphylaxis patients at emergency department. *Korean J Intern Med* 2018;33:1008-15.
61. Dribin TE, Michelson KA, Monuteaux MC, Stack AM, Farbman KS, Schneider LC, et al. Identification of children with anaphylaxis at low risk of receiving acute inpatient therapies. *PLoS One* 2019;14:e0211949.
62. Soller L, Teoh T, Baerg I, Wong T, Hildebrand KJ, Cook VE, et al. Extended analysis of parent and child confidence in recognizing anaphylaxis and using the epinephrine autoinjector during oral food challenges. *J Allergy Clin Immunol Pract* 2019;7:693-5.
63. Hamilton DK. Is emergency room care after home use of an epinephrine auto injector always needed [abstract]? *J Allergy Clin Immunol* 2019;143(suppl 2): 265.
64. Giclas HE, Robinson ML, Phillips AA, Santos CB, Lanser BJ. Comparison of anaphylaxis criteria with outpatient oral food challenge outcomes [abstract]. *J Allergy Clin Immunol Pract* 2019;143(suppl 2):164.
65. Elizur A, Appel MY, Nachshon L, Levy MB, Epstein-Rigbi N, Golobov K, et al. NUT Co Reactivity - ACquiring Knowledge for Elimination Recommendations (NUT CRACKER) study. *Allergy* 2018;73:593-601.
66. Sundquist BK, Jose J, Pauze D, Pauze D, Wang H, Järvinen KM. Anaphylaxis risk factors for hospitalization and intensive care: a comparison between adults and children in an upstate New York emergency department. *Allergy Asthma Proc* 2019;40:41-7.
67. Alen Coutinho I, Pita J, Alves M, Loureiro C, Todo Bom A. Pediatric anaphylaxis: a view from a tertiary hospital emergency department. *Allergy* 2018;73(suppl 105): 352.
68. Ponce Guevara LV, Laffond Yges E, Gracia Bara MT, Moreno Rodilla E, Muñoz Bellido FJ, Lázaro Sastre M, et al. Adherence to anaphylaxis guidelines: real-world data from the emergency department of a tertiary hospital. *J Investig Allergol Clin Immunol* 2018;28:246-52.
69. Nagakura KI, Sato S, Yanagida N, Nishino M, Asaumi T, Ogura K, et al. Oral immunotherapy in Japanese children with anaphylactic peanut allergy. *Int Arch Allergy Immunol* 2018;175:181-8.
70. Yanagida N, Sato S, Takahashi K, Nagakura KI, Asaumi T, Ogura K, et al. Increasing specific immunoglobulin E levels correlate with the risk of anaphylaxis during an oral food challenge. *Pediatr Allergy Immunol* 2018; 29:417-24.
71. Asaumi T, Yanagida N, Sato S, Shukuya A, Nishino M, Ebisawa M. Provocation tests for the diagnosis of food-dependent exercise-induced anaphylaxis. *Pediatr Allergy Immunol* 2016;27:44-9.
72. Nogie C, Belousoff J, Krieser D. The diagnosis and management of children presenting with anaphylaxis to a metropolitan emergency department: a 2-year retrospective case series. *J Paediatr Child Health* 2016;52:487-92.
73. Lee M, Stukus DR. Pre-hospital use of epinephrine for treatment of anaphylaxis in children and adolescents [abstract]. *J Allergy Clin Immunol* 2015;(suppl 1): 205.
74. Itazawa T, Ito K, Motohiro E. Severe reaction during oral food challenges in children in a prospective multicenter study. *Allergy* 2013;(suppl 98):40-1, P8-228.
75. Brennan AK, Patil SU, Fleming J, Boyce JA, Stieb ES, Nichols M, et al. Outcomes using a graded protocol for open food challenges. *J Allergy Clin Immunol* 2013; (suppl 1):86.
76. Noimark L, Wales J, Du Toit G, Pastacaldi C, Haddad D, Gardner J, et al. The use of epinephrine autoinjectors by children and teenagers. *Clin Exp Allergy* 2012;42: 284-92.
77. Dibs SD, Baker MD. Anaphylaxis in children: a 5-year experience. *Pediatrics* 1997;99:E7.
78. Cardona V, Ferré-Ybarz L, Guilarte M, Moreno-Pérez N, Gómez-Galán C, Alcoceba-Borrás E, et al. Safety of epinephrine use in anaphylaxis: a multicentre register. *Int Arch Allergy Immunol* 2017;173:171-7.
79. Alen Coutinho I, Ferreira D, Regateiro FS, Pita J, Ferreira M, Martins JF, et al. Anaphylaxis in an emergency department: a retrospective 10-year study in a tertiary hospital. *Eur Ann Allergy Clin Immunol* 2020;52:23-34.
80. Ewan PW, Clark AT. Efficacy of a management plan based on severity assessment in longitudinal and case-controlled studies of 747 children with nut allergy: proposal for good practice. *Clin Exp Allergy* 2005;35:751-6.
81. Ewan PW, Clark AT. Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan. *Lancet* 2001; 357:111-5.
82. Gold MS, Sainsbury R. First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen). *J Allergy Clin Immunol* 2000;106:171-6.
83. Zubrinich C, Douglass J, Bartlett J, Patel M, Hew M. Anaphylaxis presentations to the emergency department: impending Victorian reporting legislation. *Intern Med J* 2019;49:135-6.
84. Liu X, Lee S, Lohse CM, Hardy CT, Campbell RL. Biphasic reactions in emergency department anaphylaxis patients: a prospective cohort study. *J Allergy Clin Immunol Pract* 2020;8:1230-8.
85. Olabarri M, Gonzalez-Peris S, Vázquez P, González-Posada A, Sanz N, Vinuesa A, et al. Management of anaphylaxis in Spain: pediatric emergency care providers' knowledge. *Eur J Emerg Med* 2019;26:163-7.
86. Mehr S, Liew WK, Tey D, Tang ML. Clinical predictors for biphasic reactions in children presenting with anaphylaxis. *Clin Exp Allergy* 2009;39:1390-6.
87. Gabrielli S, Clarke A, Morris J, Eisman H, Gravel J, Enarson P, et al. Evaluation of prehospital management in a Canadian emergency department anaphylaxis cohort. *J Allergy Clin Immunol Pract* 2019;7:2232-8.e3.
88. Brough HA, Caubet JC, Mazon A, Haddad D, Bergmann MM, Wassenberg J, et al. Defining challenge-proven coexistent nut and sesame seed allergy: a prospective multicenter European study. *J Allergy Clin Immunol* 2020;145:1231-9.
89. Capucilli P, Kennedy K, Lee J, Grundmeier RW, Spergel JM. Accidental versus new food allergy reactions in a pediatric emergency department. *J Allergy Clin Immunol Pract* 2019;7:1662-4.
90. Capucilli P, Kennedy K, Alfaro M, Spergel Z, Dorris S, Spergel JM. Age Differences in food reaction severity during oral food challenges in a large pediatric population. *J Allergy Clin Immunol* 145(suppl 2): 219.
91. Chatelier J, Lin T, Stojanovic S. Risk factors associated with refractory anaphylaxis. *Internal Med J* 2019;49(suppl 4):18.
92. Cohen N, Capua T, Pivko-Levy D, Ben-Shoshan M, Rimón A, Benor S. Improved diagnosis and treatment of anaphylaxis in a pediatric emergency department (2013-2018). *J Allergy Clin Immunol Pract* 2019;7:2882-4.e2.
93. Kahveci M, Akarsu A, Koken G, Sahiner UM, Soyer O, Sekerel BE. Food-induced anaphylaxis in infants, as compared to toddlers and preschool children in Turkey. *Pediatr Allergy Immunol* 2020;31:954-61.
94. Muramatsu K, Imamura H, Tokutsu K, Fujimoto K, Fushimi K, Matsuda S. Epidemiological study of hospital admissions for food-induced anaphylaxis using the Japanese Diagnosis Procedure Combination Database [e-pub ahead of print]. *J Epidemiol*, <https://doi.org/10.2188/jea.JE20200309>. Accessed January 27, 2021.
95. Murata MA, Yamamoto LG. Patient/parent administered epinephrine in acute anaphylaxis [e-pub ahead of print]. *Am J Emerg Med*, <https://doi.org/10.1016/j.ajem.2020.10.060>. Accessed January 27, 2021.
96. Oya S, Kinoshita K, Daya M, Kinoshita H. Characteristics of anaphylactic reactions: a prospective observational study in Japan. *J Emerg Med* 2020;59:812-9.
97. Trainor JL, Pittsenbarger ZE, Joshi D, Adler MD, Smith B, Gupta RS. Outcomes and factors associated with prehospital treatment of pediatric anaphylaxis [e-pub ahead of print]. *Pediatr Emerg Care*, <https://doi.org/10.1097/PEC.0000000000002146>. Accessed January 27, 2021.
98. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. *J Allergy Clin Immunol* 2005; 115(suppl 2):S483-523.
99. Shaker M, Turner PJ, Greenhawt M. A cost-effectiveness analysis of epinephrine autoinjector risk stratification for patients with food allergy-one epinephrine autoinjector or two [e-pub ahead of print]? *J Allergy Clin Immunol Pract*, <https://doi.org/10.1016/j.jaip.2021.01.007>. Accessed January 27, 2021.